{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04715",
      "entity_text" : "Factor IX",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0454" ],
      "Cellular_component" : [ "go:GO:0018995" ],
      "Organ" : [ "uberon:UBERON:0001193" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000910" ]
    }
  },
  "verbose_text" : "Briefly, a Phase I/II dose escalation study in which patients received a hepatic artery infusion of AAV2 encoding human Factor IX initially achieved therapeutic levels of Factor IX expression.",
  "reading_complete" : "2020-08-08T17:17:22Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T17:15:20Z",
  "trigger" : "levels",
  "evidence" : [ "levels of Factor IX" ],
  "pmc_id" : "3207363",
  "score" : 0
}